Table 2.
Comparison of Characteristics Between PPH Eyes With or Without “Possible ON Damage” and “Possible Glaucoma”
| Possible ON Damage | Possible Glaucoma | |||||
|---|---|---|---|---|---|---|
| Positive | Negative | P | Positive | Negative | P | |
| Number of eyes | 23 (23.7%) | 74 (76.3%) | — | 9 (9.3%) | 88 (90.7%) | — |
| Sex | 0.330 | 0.588 | ||||
| Female | 14 (60.9%) | 53 (71.6%) | 5 (55.56%) | 62 (70.45%) | ||
| Male | 9 (39.1%) | 21 (28.4%) | 4 (44.44%) | 26 (29.55%) | ||
| Age (y), mean (SD) | 66.1 (9.8) | 67.0 (12.5) | 0.497 | 66.11 (12.30) | 66.87 (11.88) | 0.856 |
| Axial length (mm), mean (SD) | 30.85 (1.99) | 30.77 (2.26) | 0.897 | 31.12 (2.63) | 30.75 (2.12) | 0.633 |
| IOP (mm Hg), mean (SD) | 15.11 (3.72) | 15.00 (3.26) | 0.893 | 17.11 (3.84) | 14.80 (3.26) | 0.064 |
| Refractive error (D), mean (SD) | −14.19 (4.67) | −15.20 (5.67) | 0.512 | −13.81 (5.04) | −15.09 (5.55) | 0.608 |
| Median BCVA, [25%; 75%] | 0.90 [0.55; 0.95] | 0.65 [0.20; 0.98] | 0.348 | 0.60 [0.10; 0.90] | 0.80 [0.20; 1.00] | 0.311 |
| Median absorption period (d), [25%; 75%] | 182.00 [140.00; 438.50] | 182.00 [126.00; 299.25] | 0.397 | 210.00 [182.00; 511.00] | 182.00 [126.00; 302.75] | 0.198 |
| Re-hemorrhage status, eyes | ||||||
| Multiple times hemorrhages† | 12 (52.2%) | 18 (24.3%) | 0.012* | 5 (55.56%) | 25 (28.41%) | 0.194 |
| Recurrence at the same site | 8 (34.8%) | 9 (12.2%) | 0.013* | 2 (22.22%) | 15 (17.05%) | 1.000 |
| New hemorrhage at a different site | 8 (34.8%) | 10 (13.5%) | 0.022* | 4 (44.44%) | 14 (15.91%) | 0.100 |
| Category of myopic maculopathy‡ | 0.405 | 0.175 | ||||
| Diffuse atrophy (C2) | 11 (47.8%) | 24 (32.4%) | 2 (22.22%) | 33 (37.50%) | ||
| Patchy atrophy (C3) | 8 (34.8%) | 34 (45.9%) | 3 (33.33%) | 39 (44.32%) | ||
| Macular atrophy (C4) | 4 (17.4%) | 16 (21.6%) | 4 (44.44%) | 16 (18.18%) | ||
SD, standard deviation.
*
Pearson's χ2 tests.
†
Some eyes with multiple times hemorrhages recurred not only at the same site but also at a new site, so the sum number of eyes of the next two-row might surpass this row.
‡
According to META-PM study classification.